PARP14 and AL amyloidosis: Importantly, knocking down PARP14 also impaired aerobic glycolytic metabolism in other highly glycolytic human cell lines derived from multiple myeloma (RPMI-8226), brain (U87) and breast (MCF7) cancers (Supplementary Fig. 3f,g)43, 44, 45.